The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The global landscape of neurological health is undergoing a transformative moment with a pioneering nasal spray that could potentially revolutionize Alzheimer‘s disease management. As ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

Since using black market nasal tanning spray, Harper has had facial flushes, acne, and more freckles. The illegal spray can have serious side effects, according to the Therapeutic Goods ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...